Global Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Coronary Artery Disease (Ischemic Heart Disease) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including advanceCor GmbH, AgeX Therapeutics Inc, AngioSoma Inc, APT Therapeutics Inc, Ascendia Pharmaceuticals LLC and others.
A Significant contribution to the Coronary Artery Disease (Ischemic Heart Disease) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Coronary Artery Disease (Ischemic Heart Disease) pipeline included 37 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Coronary Artery Disease (Ischemic Heart Disease) condition and increased access to investments is encouraging growth of Coronary Artery Disease (Ischemic Heart Disease) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Coronary Artery Disease (Ischemic Heart Disease) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Coronary Artery Disease (Ischemic Heart Disease) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Coronary Artery Disease (Ischemic Heart Disease) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Coronary Artery Disease (Ischemic Heart Disease). Further, orphan drug status, fast track designation, grants awarded and other special status for Coronary Artery Disease (Ischemic Heart Disease) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Coronary Artery Disease (Ischemic Heart Disease) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Coronary Artery Disease (Ischemic Heart Disease) Pipeline candidates-
A Significant contribution to the Coronary Artery Disease (Ischemic Heart Disease) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Coronary Artery Disease (Ischemic Heart Disease) pipeline included 37 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Coronary Artery Disease (Ischemic Heart Disease) condition and increased access to investments is encouraging growth of Coronary Artery Disease (Ischemic Heart Disease) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Coronary Artery Disease (Ischemic Heart Disease) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Coronary Artery Disease (Ischemic Heart Disease) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Coronary Artery Disease (Ischemic Heart Disease) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Coronary Artery Disease (Ischemic Heart Disease). Further, orphan drug status, fast track designation, grants awarded and other special status for Coronary Artery Disease (Ischemic Heart Disease) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Coronary Artery Disease (Ischemic Heart Disease) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Coronary Artery Disease (Ischemic Heart Disease) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Coronary Artery Disease (Ischemic Heart Disease) drugs
- Late phase: Phase 3 and in-approval Coronary Artery Disease (Ischemic Heart Disease) drugs
- Company overview
- Snapshot
- Coronary Artery Disease (Ischemic Heart Disease) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Coronary Artery Disease (Ischemic Heart Disease)- Disease Overview
2.2 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Snapshot
2.3 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Phase
2.4 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Company
2.5 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 advanceCor GmbH Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.2 AgeX Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.3 AngioSoma Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.4 APT Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.5 Ascendia Pharmaceuticals LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.6 AstraZeneca Plc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.7 Bayer HealthCare Pharmaceuticals Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.8 Bio-Thera Solutions Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.9 Cadrock Pty Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.10 Capricor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.11 CardioVascular BioTherapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.12 CeleCor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.13 Chong Kun Dang Pharmaceutical Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.14 CSL Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.15 Cynata Therapeutics Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.16 DalCor Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.17 Diapin Therapeutics LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.18 Elevian Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.19 Gilead Sciences Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.20 Hemostemix Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.21 Idorsia Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.22 Innolife Co Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.23 Jaan Biotherapeutics LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.24 LipimetiX Development Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.25 MedImmune LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.26 Orion Corporation Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.27 Pharmahungary Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.28 Proteon Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.29 Resverlogix Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.30 Reven Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.31 Supernus Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.32 The Medicines Company Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.33 Verseon Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.34 VESSL Therapeutics Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.35 ViroMed Co Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.36 Virtual Drug Development Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.37 XyloCor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Drug Details
4.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Drug Overview
4.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Drug Details
5.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Drug Overview
5.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Details
6.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Overview
6.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Details
7.2 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Overview
7.3 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Coronary Artery Disease (Ischemic Heart Disease)- Disease Overview
2.2 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Snapshot
2.3 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Phase
2.4 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Company
2.5 Coronary Artery Disease (Ischemic Heart Disease)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 advanceCor GmbH Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.2 AgeX Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.3 AngioSoma Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.4 APT Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.5 Ascendia Pharmaceuticals LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.6 AstraZeneca Plc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.7 Bayer HealthCare Pharmaceuticals Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.8 Bio-Thera Solutions Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.9 Cadrock Pty Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.10 Capricor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.11 CardioVascular BioTherapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.12 CeleCor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.13 Chong Kun Dang Pharmaceutical Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.14 CSL Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.15 Cynata Therapeutics Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.16 DalCor Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.17 Diapin Therapeutics LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.18 Elevian Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.19 Gilead Sciences Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.20 Hemostemix Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.21 Idorsia Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.22 Innolife Co Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.23 Jaan Biotherapeutics LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.24 LipimetiX Development Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.25 MedImmune LLC Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.26 Orion Corporation Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.27 Pharmahungary Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.28 Proteon Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.29 Resverlogix Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.30 Reven Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.31 Supernus Pharmaceuticals Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.32 The Medicines Company Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.33 Verseon Corp Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.34 VESSL Therapeutics Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.35 ViroMed Co Ltd Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.36 Virtual Drug Development Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
3.37 XyloCor Therapeutics Inc Coronary Artery Disease (Ischemic Heart Disease) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Drug Details
4.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Drug Overview
4.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Drug Details
5.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Drug Overview
5.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Details
6.2 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Overview
6.3 Coronary Artery Disease (Ischemic Heart Disease)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Details
7.2 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Overview
7.3 Coronary Artery Disease (Ischemic Heart Disease)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
